Expert Interview
A Second Perspective: Discussing primary ITP and the potential of VYVGART (efgartigimod)
Ticker(s): ARGXInstitution: Mount Sinai
- Benign Hematologist (Private NY Practice) & Assistant Professor of Clinical Medicine at Icahn School of Medicine at Mount Sinai.
- Currently manages 25 patients with ITP.
- Over 20 years of experience with a clinical focus on immune thrombocytopenia.
Roughly how many patients with ITP do you currently manage?
Added By: c_adminWill efgartigimod be used for IGIV failures only? What is an IGIV failure? How many pts fail IGIV?
Added By: c_adminCan Ultomiris or Soliris be used instead of Fcrn?
Added By: c_adminPlease describe how you currently manage patients with ITP
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
